Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 550

1.

Toward the potential cure of leukemias in the next decade.

Kantarjian HM, Keating MJ, Freireich EJ.

Cancer. 2018 Nov 15;124(22):4301-4313. doi: 10.1002/cncr.31669. Epub 2018 Oct 6. Review. Erratum in: Cancer. 2019 May 15;125(10):1756.

2.

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.

Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ.

Cancer. 2018 Jun 15;124(12):2534-2540. doi: 10.1002/cncr.31370. Epub 2018 Apr 12.

3.

Proceedings of the Third Annual Meeting of the Society of Hematologic Oncology.

List AF, Kantarjian H, Freireich EJ.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S1. doi: 10.1016/j.clml.2016.07.001. No abstract available.

PMID:
27521304
4.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.

Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ.

Blood. 2016 Jan 21;127(3):303-9. doi: 10.1182/blood-2015-09-667675. Epub 2015 Oct 22.

5.

The proceedings of the initial meeting of the Society of Hematologic Oncology 2013.

Freireich EJ, Kantarjian H, Keating MJ.

Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S1. doi: 10.1016/j.clml.2014.08.001. No abstract available.

PMID:
25486946
6.

The leukemias: a half-century of discovery.

Freireich EJ, Wiernik PH, Steensma DP.

J Clin Oncol. 2014 Nov 1;32(31):3463-9. doi: 10.1200/JCO.2014.57.1034. Epub 2014 Sep 2. Review.

PMID:
25185093
7.

Granulocyte concentrates from a single high-yield apheresis can be split to support multiple patients.

Aung FM, Lichtiger B, Bassett RL, Hosing C, Freireich EJ.

Leuk Lymphoma. 2014 Nov;55(11):2577-83. doi: 10.3109/10428194.2014.883619. Epub 2014 Feb 24.

PMID:
24456072
8.

Retrospect of hematological malignancies 2012.

Freireich EJ, Kantarjian H, Keating MJ.

Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S271. doi: 10.1016/j.clml.2013.08.001. No abstract available.

PMID:
24290211
9.

Emil Frei III, 1924-2013.

Holland JF, Freireich EJ.

J Clin Oncol. 2013 Oct 20;31(30):3727-30. doi: 10.1200/JCO.2013.51.8126. Epub 2013 Sep 9. No abstract available.

PMID:
24019548
10.

The history of leukemia therapy--a personal journey.

Freireich EJ.

Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):386-92. doi: 10.1016/j.clml.2012.09.014. Review.

PMID:
23158094
11.

The Society of Hematologic Oncology (SOHO): moving forward in the battle against hematologic malignancies.

Freireich EJ.

Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):385. doi: 10.1016/j.clml.2012.10.001. No abstract available.

PMID:
23158093
12.

The african organization for research and training in cancer.

Freireich EJ.

Curr Oncol. 2012 Oct;19(5):245. doi: 10.3747/co.19.1102. No abstract available.

13.

A prospective, randomized, double-blind study, comparing unirradiated to irradiated white blood cell transfusions in acute leukemia patients.

Freireich EJ, Lichtiger B, Mattiuzzi G, Martinez F, Reddy V, Kyle Wathen J.

Leukemia. 2013 Apr;27(4):861-5. doi: 10.1038/leu.2012.301. Epub 2012 Oct 17.

14.

Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies.

Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE.

Haematologica. 2013 Feb;98(2):217-21. doi: 10.3324/haematol.2012.071092. Epub 2012 Aug 8.

15.

The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells.

Cheng X, Quintás-Cardama A, Golemovic M, Zingaro R, Gao MZ, Freireich EJ, Andreeff M, Kantarjian HM, Verstovsek S.

Anticancer Res. 2012 Jul;32(7):2871-80.

16.

Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.

Kadia TM, Kantarjian H, Kornblau S, Borthakur G, Faderl S, Freireich EJ, Luthra R, Garcia-Manero G, Pierce S, Cortes J, Ravandi F.

Cancer. 2012 Nov 15;118(22):5550-9. doi: 10.1002/cncr.27596. Epub 2012 May 8.

17.

Retrospect of hematologic malignancies 2010.

Cortés JE, Freireich EJ, Kantarjian H, Verstovsek S.

Clin Lymphoma Myeloma Leuk. 2011 Jun;11 Suppl 1:S1. doi: 10.1016/j.clml.2011.05.038. Epub 2011 May 23. No abstract available.

PMID:
22035736
18.

The 6-MP versus placebo clinical trial in acute leukemia.

Gehan EA, Freireich EJ.

Clin Trials. 2011 Jun;8(3):288-97. doi: 10.1177/1740774511407358.

PMID:
21730077
19.

Leukocyte transfusion and the development of the continuous-flow blood cell separator.

Freireich EJ.

Transfus Med Rev. 2011 Oct;25(4):344-50. doi: 10.1016/j.tmrv.2011.04.004. Epub 2011 May 31.

PMID:
21632206
20.

Twenty-five years of peripheral blood stem cell transplantation.

Körbling M, Freireich EJ.

Blood. 2011 Jun 16;117(24):6411-6. doi: 10.1182/blood-2010-12-322214. Epub 2011 Apr 1. Review.

PMID:
21460243
21.

Origins of platelet transfusion therapy.

Freireich EJ.

Transfus Med Rev. 2011 Jul;25(3):252-6. doi: 10.1016/j.tmrv.2011.01.003. Epub 2011 Mar 2. Review.

PMID:
21371858
22.

LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients.

Duzkale H, Schweighofer CD, Coombes KR, Barron LL, Ferrajoli A, O'Brien S, Wierda WG, Pfeifer J, Majewski T, Czerniak BA, Jorgensen JL, Medeiros LJ, Freireich EJ, Keating MJ, Abruzzo LV.

Blood. 2011 Apr 14;117(15):4076-84. doi: 10.1182/blood-2010-09-304881. Epub 2011 Feb 10.

23.

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.

Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ.

Blood. 2010 Nov 25;116(22):4422-9. doi: 10.1182/blood-2010-03-276485. Epub 2010 Jul 28.

24.

The road to cancer control goes through leukemia research.

Freireich EJ.

Curr Oncol. 2009 Sep;16(5):1-2. No abstract available.

25.

Leukemia research, 2008.

Freireich EJ, Kantarjian H, Keating MJ.

Clin Lymphoma Myeloma. 2009;9 Suppl 3:S178. doi: 10.3816/CLM.2009.s.008. No abstract available.

PMID:
19778837
26.

Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.

Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F.

Leukemia. 2009 Dec;23(12):2275-80. doi: 10.1038/leu.2009.181. Epub 2009 Sep 10.

27.

MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells.

Golemovic M, Quintás-Cardama A, Manshouri T, Orsolic N, Duzkale H, Johansen M, Freireich EJ, Kantarjian H, Zingaro RA, Verstovsek S.

Invest New Drugs. 2010 Aug;28(4):402-12. doi: 10.1007/s10637-009-9267-z. Epub 2009 May 26.

28.
29.

Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.

Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ, Kantarjian HM, Keating MJ.

J Clin Oncol. 2009 Feb 20;27(6):904-10. doi: 10.1200/JCO.2008.17.5398. Epub 2008 Dec 29.

30.

The role of investigational therapy in management of patients with advanced metastatic malignancy.

Freireich EJ, Kurzrock R.

J Clin Oncol. 2009 Jan 10;27(2):304-6. doi: 10.1200/JCO.2008.19.6543. Epub 2008 Dec 8. No abstract available.

PMID:
19064962
31.

Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.

Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Garcia-Manero G, Issa JP, Estey E, Keating M, Freireich EJ.

Cancer. 2008 Oct 1;113(7 Suppl):1933-52. doi: 10.1002/cncr.23655. Review.

32.

Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.

Tsimberidou AM, Kantarjian HM, Wen S, Keating MJ, O'Brien S, Brandt M, Pierce S, Freireich EJ, Medeiros LJ, Estey E.

Cancer. 2008 Sep 15;113(6):1370-8. doi: 10.1002/cncr.23691.

33.

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.

Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, Freireich EJ, Garcia-Manero G.

Cancer. 2008 Sep 15;113(6):1351-61. doi: 10.1002/cncr.23697.

34.

The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients.

Tsimberidou AM, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ, Keating MJ, Estey EH.

Clin Cancer Res. 2008 Feb 1;14(3):721-30. doi: 10.1158/1078-0432.CCR-07-2063.

35.

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center.

Tsimberidou AM, Wen S, O'Brien S, McLaughlin P, Wierda WG, Ferrajoli A, Faderl S, Manning J, Lerner S, Mai CV, Rodriguez AM, Hess M, Do KA, Freireich EJ, Kantarjian HM, Medeiros LJ, Keating MJ.

J Clin Oncol. 2007 Oct 10;25(29):4648-56.

PMID:
17925562
36.

Should terminally ill patients have the right to take drugs that pass phase I testing? Yes.

Freireich EJ.

BMJ. 2007 Sep 8;335(7618):478. No abstract available.

37.

Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.

Atallah E, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ, Kantarjian H.

Blood. 2007 Nov 15;110(10):3547-51. Epub 2007 Aug 2.

PMID:
17673605
38.

Lesson on leukemia.

Freireich EJ.

J BUON. 2002 Jan-Mar;7(1):9-11. No abstract available.

PMID:
17577253
39.

Randomization in Phase II Clinical Trials.

Yothers G, Wieand S, Freireich EJ.

Clin Adv Hematol Oncol. 2006 Oct;4(10):776-8. Review. No abstract available.

PMID:
17111561
40.

Influence of high-efficiency particulate air filtration on mortality and fungal infection: a rebuttal.

Bodey GP, Freireich EJ.

J Infect Dis. 2006 Dec 1;194(11):1621-2; author reply 1622-3. No abstract available.

PMID:
17083053
41.

Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome.

Montero AJ, Estrov Z, Freireich EJ, Khouri IF, Koller CA, Kurzrock R.

Leuk Lymphoma. 2006 Oct;47(10):2049-54.

PMID:
17071475
42.

Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.

Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do KA, Smith SC, Lerner S, Freireich EJ, Keating MJ.

J Clin Oncol. 2006 May 20;24(15):2343-51.

PMID:
16710033
43.

Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.

Safdar A, Rodriguez GH, Lichtiger B, Dickey BF, Kontoyiannis DP, Freireich EJ, Shpall EJ, Raad II, Kantarjian HM, Champlin RE.

Cancer. 2006 Jun 15;106(12):2664-71.

44.

Eradication of minimal residual disease in hairy cell leukemia.

Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM.

Blood. 2006 Jun 15;107(12):4658-62. Epub 2006 Feb 23.

PMID:
16497968
45.

The investigational new drug application--who benefits?

Freireich EJ.

Nat Clin Pract Oncol. 2006 Feb;3(2):62-3. No abstract available.

PMID:
16462826
46.

Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.

Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O'Brien S, Freireich EJ, Garcia-Manero G, Kantarjian H, Verstovsek S.

Cancer. 2005 Jun 15;103(12):2551-7.

47.

Metastasis--an alternative hypothesis.

Freireich EJ, Kurzrock R, Estrov Z.

Cancer. 2005 Apr 15;103(8):1537-9. Review.

48.

Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections.

Safdar A, Hanna HA, Boktour M, Kontoyiannis DP, Hachem R, Lichtiger B, Freireich EJ, Raad II.

Cancer. 2004 Dec 15;101(12):2859-65.

49.

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.

Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ.

Cancer. 2004 Dec 15;101(12):2788-801.

50.

Hairy cell leukemia with large cells: long disease course with adequate response to therapy.

Sun X, Amin HM, Freireich EJ, Keating MJ, Kantarjian HM, Koller CA, O'Brien SM, Giles F, Albitar M.

Leukemia. 2004 Nov;18(11):1912-4. No abstract available.

PMID:
15385931

Supplemental Content

Loading ...
Support Center